Three Firms Fined £100M For Overpriced Thyroid Drug
Britain's antitrust watchdog said Thursday it has hit Advanz and two other companies with more than £100 million ($140 million) in fines after finding that the drugmaker had inflated the price...To view the full article, register now.
Already a subscriber? Click here to view full article